文献速递血管炎

ANCA特异性对ANCA相关血管炎心血管事件及死亡风险的影响

Impact of ANCA specificity on risk of cardiovascular events and death in ANCA-associated vasculitis.
PubMed 文献 · RMD Open · 2026-01-22

基于ANCA相关血管炎Toulouse队列的回顾性研究,纳入402例患者,比较抗PR3与抗MPO ANCA患者主要不良心血管事件(MACE)风险。抗MPO组MACE发生率33.1/1000患者年高于抗PR3组21.4/1000患者年(p=0.036),抗MPO组诊断至MACE时间更短,但校正后HR 1.62(95%CI 0.98-2.66;p=0.06)未达统计学显著。抗PR3与卒中风险降低相关(HR 0.61;95%CI 0.37-0.99;p=0.049)。

要点

  • 抗MPO ANCA患者MACE发生率高于抗PR3组(33.1 vs 21.4/1000患者年,p=0.036)。
  • 抗MPO组从AAV诊断至MACE发生的时间显著更短。
  • 抗PR3 ANCA与卒中风险降低独立相关(HR 0.61;95%CI 0.37-0.99;p=0.049)。

核心结论

  • 抗MPO ANCA患者相比抗PR3 ANCA患者呈现更高的复合MACE-全因死亡结局风险。
  • 抗PR3 ANCA与较低的卒中风险相关(HR 0.61;95%CI 0.37-0.99;p=0.049),与心肌梗死风险无关。

研究设计与样本

  • 回顾性研究,使用ANCA相关血管炎Toulouse队列,共纳入402例患者。
  • 166例(41%)为抗PR3 ANCA,236例(59%)为抗MPO ANCA。
  • MACE定义为心肌梗死和/或卒中和/或全因死亡,按ANCA特异性比较发生率,并采用校正传统心血管危险因素、年龄和性别的Cox回归模型。

主要发现

  • 随访期间共识别78例MACE,包括15例心肌梗死、12例卒中和62例死亡。
  • 抗PR3组MACE发生率为21.4/1000患者年,抗MPO组为33.1/1000患者年(p=0.036)。
  • 抗MPO组从AAV诊断至MACE发生的时间显著更短。
  • Cox回归显示抗MPO ANCA患者倾向更多MACE,但无统计学显著性(HR 1.62;95%CI 0.98-2.66;p=0.06)。
  • 抗PR3 ANCA与卒中风险降低相关(HR 0.61;95%CI 0.37-0.99;p=0.049),与心肌梗死风险无关联。

关键数值与推荐

  • MACE发生率:抗PR3组21.4/1000患者年 vs 抗MPO组33.1/1000患者年(p=0.036)。
  • 抗MPO ANCA与MACE关联的HR 1.62(95%CI 0.98-2.66;p=0.06)。
  • 抗PR3 ANCA与卒中关联的HR 0.61(95%CI 0.37-0.99;p=0.049)。

临床怎么用

  • 对AAV患者应关注ANCA特异性,抗MPO ANCA患者可能需更积极的心血管风险评估与监测。
  • 抗PR3 ANCA患者卒中风险相对较低,但仍需按常规管理传统心血管危险因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to investigate the relationship between antineutrophil cytoplasmic antibodies (ANCA) specificity and the risk of major adverse cardiovascular events (MACE) in patients with ANCA-associated vasculitis (AAV). METHODS: We conducted a retrospective study using the ANCA-associated vasculitis Toulouse cohort. The incidence of MACE, defined as myocardial infarction (MI) and/or stroke and/or all-cause death, was compared among patients according to their ANCA specificity. We also applied Cox regression models adjusted for traditional cardiovascular risk factors, age and sex to assess the risk of MI, stroke and MACE. RESULTS: A total of 402 patients were included, of whom 166 (41%) had antiproteinase 3 (anti-PR3) ANCA and 236 (59%) had antimyeloperoxidase (anti-MPO) ANCA. We identified 78 MACE during the follow-up period, including 15 MIs, 12 strokes and 62 deaths. The incidence rate of MACE in the ANCA+anti-PR3+ group was 21.4 per 1000 patient-years compared with 33.1 per 1000 patient-years in the ANCA+anti-MPO+ group (p=0.036). The time elapsed between the diagnosis of AAV and MACE occurrence was significantly shorter in the ANCA+anti-MPO+ group. The Cox regression model found that patients with anti-MPO ANCA tend to present more MACE, but the association was not statistically significant (HR 1.62; 95% CI 0.98 to 2.66; p=0.06). An association was found between the presence of anti-PR3 ANCA and a lower risk of strokes (HR 0.61; 95% CI 0.37 to 0.99; p=0.049) and none with the risk of MI. CONCLUSION: Patients with anti-MPO ANCA appear to be at a higher risk of a composite MACE-all-cause mortality outcome than patients with anti-PR3 ANCA.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Idoate Lacasia J, Mourguet M, Villeneuve T, et al. Impact of ANCA specificity on risk of cardiovascular events and death in ANCA-associated vasculitis. RMD Open. 2026. PMID: 41571323. doi:10.1136/rmdopen-2025-006085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。